Lipocine Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
LPCN$1.59-7.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Years Ended December 31, | |||
|---|---|---|---|
| 2024 · 2023 | |||
| Cash flows from operating activities: | |||
| Net income (loss) | $8,352 | $(16,352,082) | |
| Adjustments to reconcile net income (loss) to cash used in operating activities: | |||
| Depreciation expense | 41,106 | 28,661 | |
| Stock-based compensation expense | 408,551 | 654,438 | |
| Non-cash gain on change in fair value of warrant liability | (17,166) | (212,690) | |
| Amortization of discounts on marketable investment securities | (697,865) | (952,651) | |
| Write off of contract asset due to variable consideration revenue reversal | - | 2,960,805 | |
| Changes in operating assets and liabilities: | |||
| Accrued interest income | (68,193) | 28,173 | |
| Contract asset | - | 709,933 | |
| Prepaid and other current assets | 205,509 | 333,085 | |
| Accounts payable | (1,124,281) | 795,589 | |
| Accrued expenses | (297,246) | 140,748 | |
| Deferred revenue | 320,000 | - | |
| Cash used in operating activities | (1,221,233) | (11,865,991) | |
| Cash flows from investing activities: | |||
| Purchase of property and equipment | (90,086) | (13,167) | |
| Purchases of marketable investment securities | (32,863,853) | (22,902,147) | |
| Maturities of marketable investment securities | 35,400,000 | 36,000,000 | |
| Cash provided by investing activities | 2,446,061 | 13,084,686 | |
| Cash flows from financing activities: | |||
| Net proceeds from sale of common stock through ATM | 209,340 | 404,567 | |
| Cash provided by financing activities | 209,340 | 404,567 | |
| Net increase in cash and cash equivalents | 1,434,168 | 1,623,262 | |
| Cash and cash equivalents at beginning of period | 4,771,758 | 3,148,496 | |
| Cash and cash equivalents at end of period | $6,205,926 | $4,771,758 | |
| Supplemental disclosure of cash flow information: | |||
| Income taxes paid | $681 | 225 | |
| Supplemental disclosure of non-cash investing and financing activity: | |||
| Net unrealized gain on available-for-sale securities | $1,879 | $27,580 | |
| Issuance of Series B preferred stock | $ | - | $89 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.